0.29
Precedente Chiudi:
$0.231
Aprire:
$0.296
Volume 24 ore:
200.94M
Relative Volume:
38.11
Capitalizzazione di mercato:
$14.47M
Reddito:
-
Utile/perdita netta:
$-60.11M
Rapporto P/E:
-0.0667
EPS:
-4.347
Flusso di cassa netto:
$-12.04M
1 W Prestazione:
+13.86%
1M Prestazione:
+4.54%
6M Prestazione:
-74.78%
1 anno Prestazione:
-60.76%
AEON Biopharma Inc. Stock (AEON) Company Profile
Nome
AEON Biopharma Inc.
Settore
Industria
Telefono
(949) 354-6499
Indirizzo
5 Park Plaza, Suite 1750, Irvine
Compare AEON vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
AEON
AEON Biopharma Inc.
|
0.29 | 11.52M | 0 | -60.11M | -12.04M | -4.347 |
|
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
|
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
|
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
AEON Biopharma Inc. Stock (AEON) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-08-18 | Iniziato | H.C. Wainwright | Buy |
AEON Biopharma Inc. Borsa (AEON) Ultime notizie
12 Health Care Stocks Moving In Thursday's After-Market Session - benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session - benzinga.com
$AEON Biopharma (AEON.US)$ interesting. got it marked from 2025 not sure why lmao - Moomoo
12 Health Care Stocks Moving In Thursday's Pre-Market Session - benzinga.com
The rocket is about to launch 😘 - Moomoo
$AEON Biopharma (AEON.US)$ - Moomoo
Laidlaw initiates Aeon Biopharma stock coverage with buy rating By Investing.com - Investing.com Australia
12 Health Care Stocks Moving In Wednesday's After-Market Session - benzinga.com
AEON Biopharma, Inc. Announces Positive Pilot Forced Degradation Results Supporting Analytical Comparability of Abp-450 to Botox - marketscreener.com
AEON Announces Positive Pilot Forced Degradation Results Supporting Analytical Comparability of ABP-450 to BOTOX - marketscreener.com
BOTOX and ABP-450 each fell to about half strength by day 14 - Stock Titan
Laidlaw initiates Aeon Biopharma stock coverage with buy rating - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
AEON Biopharma to Participate in Lake Street Capital Markets’ 10th Annual Best Ideas Growth (BIG10) Conference - The Manila Times
AEON Biopharma to Host Investor Meetings at Lake Street Capital Markets’ 10th Annual BIG10 Conference - Quiver Quantitative
Insider Purchase: 10% Owner at $AEON Buys 1,150,000 Shares - Moomoo
AEON Biopharma names Paul Lee as acting chief regulatory officer By Investing.com - Investing.com Nigeria
A Former FDA Neuroscience Deputy Will Guide AEON’s BOTOX Biosimilar - Stock Titan
Aeon Biopharma director Timothy Lynch buys $243,455 in stock - Investing.com India
Timothy Lynch (NASDAQ: AEON) owns 13% and holds blocked warrants - Stock Titan
AEON Reports New Data on Botox Biosimilar - Orange County Business Journal
Lake Street Maintains AEON Biopharma(AEON.US) With Buy Rating, Maintains Target Price $1 - Moomoo
AEON Flat on BOTOX Developments - Baystreet.ca
META_TITLE_QUOTE - Yahoo Finance
AEON Reports Expanded Structural Data Supporting Molecular Similarity of ABP-450 to BOTOX® - The Manila Times
AEON Biopharma (AEON) Steadies at $0.28 as Key Support HoldsVolume Gap - vinanet.vn
H.C. Wainwright cuts Aeon Biopharma stock price target on dilution - Investing.com
H.C. Wainwright cuts Aeon Biopharma stock price target on dilution By Investing.com - Investing.com UK
AEON Biopharma (AEON) Holds Above $0.27 Support as Shares Edge Up 1.66%Extension Target - vinanet.vn
AEON Q4 2025 Earnings: Wider-than-Expected Loss of -$0.42 per Share as Revenue Remains Absent - vinanet.vn
H.C. Wainwright Maintains AEON Biopharma(AEON.US) With Buy Rating, Cuts Target Price to $1.2 - Moomoo
AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
AEON Biopharma Q2 EPS $(0.02) beats $(0.12) estimate - scanx.trade
AEON Biopharma Reports Q2 Results, Advances ABP-450 Program - TipRanks
AEON Biopharma Q2 net loss narrows on warrant gain; cash runway extended - TradingView
AEON Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
AEON BIOPHARMA INC Q2 EBIT USD -5.919 MILLION - Moomoo
Aeon Biopharma Inc (AEON) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
AEON Biopharma Regains Compliance with NYSE American Continued Listing Standards - The Manila Times
Aeon Biopharma Inc (AEON) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
AEON Biopharma Regains NYSE American Listing Compliance - TipRanks
AEON Biopharma Regains NYSE American Compliance After Completing Public Offering - Quiver Quantitative
AEON Biopharma (NYSE American: AEON) lifts .BC indicator after $13.6M equity raise - Stock Titan
AEON Q4 2025 Earnings: Wider Loss of -$0.42 Per Share Overshadowed by 14.81% Stock SurgeHealthcare Earnings Report - vinanet.vn
AEON Q4 2025 Earnings: Deep EPS Miss Overshadowed by 14.81% Share RallyPeak Earnings Alert - vinanet.vn
AEON Biopharma, Inc. Revenue Breakdown – AMEX:AEON - TradingView
Aeon Biopharma Inc (AEON) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
AEON|Aeon Biopharma Inc|Price:0.257|Chg%:+0.006 - TradingKey
Aeon Biopharma Inc (AEON) Valuation: PE, PB & Fair Value Analysis - TradingKey
Aeon Biopharma Inc (AEON) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Aeon Biopharma Inc (AEON) Income Statement - TradingKey
AEON Biopharma Inc. Azioni (AEON) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Capitalizzazione:
|
Volume (24 ore):